期刊文献+

Effects of Sulfate Chitosan Derivatives on Nonalcoholic Fatty Liver Disease

Effects of Sulfate Chitosan Derivatives on Nonalcoholic Fatty Liver Disease
下载PDF
导出
摘要 Sulfate chitosan derivatives have good solubility and therapeutic effect on the cell model of NAFLD. The aim of this study was to examine the therapeutic effect of sulfate chitosan derivatives on NAFLD. The male Wistar rats were orally fed high fat emulsion and received sulfate chitosan derivatives for 5 weeks to determine the pre-treatment effect of sulfate chitosan derivatives on NAFLD. To evaluate the therapeutic effect of sulfate chitosan derivatives on NAFLD, the rats were orally fed with high concentration emulsion for 5 weeks, followed by sulfate chitosan derivatives for 3 weeks. Histological analysis and biomedical assays showed that sulfate chitosan derivatives can dramatically prevent the development of hepatic steatosis in hepatocyte cells. In animal studies, pre-treatment and treatment with sulfate chitosan derivatives significantly protected against hepatic steatohepatitis induced by high fat diet according to histological analysis. Furthermore, increased TC, ALT, MDA, and LEP in NAFLD were significantly ameliorated by pre-treatment and treatment with sulfate chitosan derivatives. Furthermore, increased TG, AST, and TNF-α in NAFLD were significantly ameliorated by treatment with sulfate chitosan derivatives. Sulfate chitosan derivatives have good pre-treatment and therapeutic effect on NAFLD. Sulfate chitosan derivatives have good solubility and therapeutic effect on the cell model of NAFLD. The aim of this study was to examine the therapeutic effect of sulfate chitosan derivatives on NAFLD. The male Wistar rats were orally fed high fat emulsion and received sulfate chitosan derivatives for 5 weeks to determine the pre-treatment effect of sulfate chitosan derivatives on NAFLD. To evaluate the therapeutic effect of sulfate chitosan derivatives on NAFLD, the rats were orally fed with high concentra-tion emulsion for 5 weeks, followed by sulfate chitosan derivatives for 3 weeks. Histological analysis and biomedical assays showed that sulfate chitosan derivatives can dramatically prevent the development of hepatic steatosis in hepatocyte cells. In animal studies, pre-treatment and treatment with sulfate chitosan derivatives significantly protected against hepatic steatohepatitis induced by high fat diet according to histological analysis. Furthermore, increased TC, ALT, MDA, and LEP in NAFLD were significantly amelio-rated by pre-treatment and treatment with sulfate chitosan derivatives. Furthermore, increased TG, AST, and TNF-α in NAFLD were significantly ameliorated by treatment with sulfate chitosan derivatives. Sulfate chitosan derivatives have good pre-treatment and therapeutic effect on NAFLD.
出处 《Journal of Ocean University of China》 SCIE CAS 2014年第3期531-537,共7页 中国海洋大学学报(英文版)
基金 supported by the National High Technology Research and Development Program of China (863 Program 2006AA090401)
关键词 NAFLD sulfate chitosan derivatives histological analysis hepatocyte cells RATS 壳聚糖硫酸酯 壳聚糖衍生物 高脂肪 Wistar大鼠 酒精性 治疗效果 肝病 多糖衍生物
  • 相关文献

参考文献1

二级参考文献16

  • 1杨坤,孔华丽,黄正明.脂肪肝动物实验模型的方法学研究进展[J].解放军药学学报,2005,21(5):374-376. 被引量:13
  • 2张之,毛新民,李琳琳,王长辉,杨永新,聂小艳.酒脂混合溶液建立酒精性脂肪肝大鼠模型的方法探讨[J].新疆中医药,2006,24(5):19-22. 被引量:3
  • 3刘嵩,卢笑丛,葛建,王有为.高脂所致脂肪肝动物模型建立的动态研究[J].中国药理学通报,2006,22(11):1399-1402. 被引量:24
  • 4贾晨光,宋建亭,苏津蕊,陈治清.脂肪肝及其药物治疗[J].中国医药,2007,2(6):382-384. 被引量:6
  • 5Yin HQ,Kim YC,Chung YS,et al.Honokiol reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element binding protein-1c and the expression of its downstream lipogenesis genes[J].Toxicology and Applied Pharmacology,2009,236(1):124-130. 被引量:1
  • 6Bradbury,Michael W.Lipid metabolism and liver inflammation.I.Hepatic fatty acid uptake:possible role in steatosis[J].American journal of physiology,Gastrointestinal and liver physiology,2006,290(2):G194-G198. 被引量:1
  • 7Farrell Geoffrey C,Larter Claire Z.Nonalcoholic fatty liver disease:from steatosis to cirrhosis[J].Hepatology,2006,43(2 Suppl 1):S99-S112. 被引量:1
  • 8Merat Shahin,Malekzadeh Reza,Sohrabi Masoud.et al.Probucol in the treatment of non-alcoholic steatohepatitis:a double-blind randomized controlled study[J].Journal of Hepatology,2003,38(4):414-418. 被引量:1
  • 9Rallidis LS,Drakoulis CK,Parasi AS.Pravastatin in patients with nonalcoholic steatohepatitis:results of a pilot study[J].Atherosclerosis,2004,174(1):193-196. 被引量:1
  • 10G mez-Dom nguez E,Gisbert JP,Moreno-Monteagudo JA,et al.A pilot study of atorvastatin treatment in dyslipemid,non-alcoholic fatty liver patients[J].Alimentary Pharmacology & Therapeutics,2006,23(11):1643-1647. 被引量:1

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部